In the news
Teva gains U.S. approval for higher-dose Copaxone therapy - Bloomberg News
January 28, 2014
Teva Pharmaceutical Industries Ltd. (TEVA) gained U.S. approval for a longer-acting version of the Copaxone multiple-sclerosis drug, bolstering the company's effort to defend its best-selling product as competitors seek to introduce cheaper copies this year. Teva can now market Copaxone for use as a 40-milligram shot three times a week, the Petach Tikva, Israel-based company said yesterday in a statement. The approval "is a significant advancement for patients as they now have the option of effective and safe treatment with Copaxone, while reducing the number of injections by 60 percent," Omar Khan, chair of the Department of Neurology at Wayne State University School of Medicine, said in the statement. "Patients in the U.S. can now benefit from an improved dosing regimen without compromising the known benefits of Copaxone."